Greenberg Traurig LLP issued the following announcement on Oct. 4.
Global law firm Greenberg Traurig, LLP represented CNS Network and Hassman Research Institute in a strategic merger to form Apex Innovative Sciences, Inc., an independent operator of clinical trial sites, focused on complex clinical trial studies for central nervous system indications. In the three-company M&A transaction, Apex acquired Clinical Trial Centers Alliance, which coordinates clinical trial site studies for sponsors and clinical research organizations. Bison Capital Partners V, LP, a private equity firm, participated in the formation of Apex with an equity investment.
“We were pleased to represent CNS Network and Hassman Research Institute in this significant merger,” said Mark J. Kelson, chair of Greenberg Traurig’s Los Angeles Corporate Practice, who led the firm’s deal team. “With this merger CNS and HRI have noted they can expand their impact, cover a broader geographic footprint, and combine decades of scientific, technological, and clinical expertise.”
Greenberg Traurig’s multi-office deal team consisted of members of the firm’s Corporate, Health Care, Tax, Benefits and Compensation, and ERISA practices. In addition to Kelson, Corporate team members included shareholder Jack McBride; of counsel John J. Loncto and Zachary A. Luber; and associates Benjamin J. Einbinder, Jennifer Kutsunai, Katie N. Saucier, Lyra Haas, Omar Parra, and Charles Lilly. Healthcare team members included shareholders Michi Tsuda and Julie A. Sullivan; and associates Renae Nanna and Merlow Dunham. Tax, Benefits and Compliance, and ERISA team members included shareholders Noam Lipshitz, Leanne Reagan, and Brandon G. Feingold; of counsel John Prusiecki; and associate Claire Arritola.
Original source can be found here.